Amgen Inc. $AMGN Shares Sold by Mattern Capital Management LLC

Key Points

• Mattern Capital trimmed its stake in Amgen (AMGN) by 9.7% in Q4, selling 3,728 shares to hold 34,576 shares worth about $11.32M, and institutional investors now own roughly 76.5% of the company.
• Amgen will report Q1 2026 results after the close on April 30, a near‑term volatility driver — pre‑earnings previews suggest a potential Q1 earnings decline, though Amgen beat the prior quarter and set FY2026 EPS guidance of 21.60–23.00.
• Pipeline and analyst signals: Amgen completed an early Phase 1/2 MTAP‑null cancer combination study (a de‑risking milestone), while analysts remain mixed with an average price target near $356.62.

Mattern Capital Management LLC lessened its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 9.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 34,576 shares of the medical research company's stock after selling 3,728 shares during the quarter. Amgen makes up 1.3% of Mattern Capital Management LLC's holdings, making the stock its 14th biggest position. Mattern Capital Management LLC's holdings in Amgen were worth $11,317,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. West Family Investments Inc. grew its position in Amgen by 1.1% during the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company's stock valued at $779,000 after buying an additional 30 shares during the period. Viawealth LLC grew its position in Amgen by 0.4% during the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company's stock valued at $2,023,000 after buying an additional 30 shares during the period. LOM Asset Management Ltd grew its position in Amgen by 1.2% during the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company's stock valued at $721,000 after buying an additional 30 shares during the period. Sittner & Nelson LLC grew its position in Amgen by 0.4% during the third quarter. Sittner & Nelson LLC now owns 7,276 shares of the medical research company's stock valued at $2,053,000 after buying an additional 30 shares during the period. Finally, Smith Salley Wealth Management lifted its holdings in Amgen by 0.3% during the fourth quarter. Smith Salley Wealth Management now owns 10,786 shares of the medical research company's stock valued at $3,530,000 after purchasing an additional 30 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported completion of an early Phase 1/2 MTAP‑null cancer combination study — a clinical milestone that can de‑risk a development program and supports longer‑term oncology pipeline value. Company Study Completion
• Positive Sentiment: Guggenheim nudged its price target on AMGN to $351 (maintaining a Neutral rating), which signals modest analyst upside versus the stock’s trading range and can provide short‑term support. Guggenheim PT Update
• Neutral Sentiment: Amgen confirmed it will report Q1 2026 results after the market close on April 30 and will host a webcast — an obvious near‑term volatility driver as investors adjust positions into the print. Q1 Webcast
• Neutral Sentiment: Legislation (H.R. 8203) expanding workforce and treatment funding for substance use disorders was introduced; Amgen is listed among relevant healthcare companies — this is a longer‑horizon policy item that could modestly affect labor/training dynamics but is unlikely to move the stock immediately. H.R.8203 Bill
• Negative Sentiment: Pre‑earnings previews from Zacks and Yahoo Finance suggest AMGN may report a decline in Q1 earnings (reducing the odds of an earnings beat), which increases downside risk into the report. Earnings Preview
• Negative Sentiment: Insiders sold roughly US$4.1M of Amgen stock over the past year — sizable insider selling can be perceived as a cautionary signal by some investors. Insider Selling
• Neutral Sentiment: Amgen announced the planned retirement of EVP & Chief Technology Officer David M. Reese effective June 30, 2026, with a strategic leadership realignment — a governance event to watch, but presented as orderly and planned. CTO Retirement

Analysts Set New Price Targets

AMGN has been the topic of several recent analyst reports. Wall Street Zen downgraded shares of Amgen from a "buy" rating to a "hold" rating in a report on Saturday. Rothschild & Co Redburn increased their price objective on shares of Amgen from $180.00 to $200.00 and gave the company a "sell" rating in a report on Wednesday, February 18th. Daiwa Securities Group boosted their price target on shares of Amgen from $370.00 to $410.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 10th. Sanford C. Bernstein downgraded shares of Amgen from an "outperform" rating to a "market perform" rating and set a $335.00 price objective for the company. in a report on Tuesday, January 20th. Finally, Barclays assumed coverage on shares of Amgen in a report on Friday, February 20th. They issued an "equal weight" rating and a $350.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $356.62.

Amgen Stock Down 1.2%

AMGN stock opened at $344.55 on Friday. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The firm has a 50-day moving average of $360.74 and a two-hundred day moving average of $339.15. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29. The company has a market cap of $185.95 billion, a price-to-earnings ratio of 24.21, a PEG ratio of 3.64 and a beta of 0.47.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts' consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same period in the previous year, the firm earned $5.31 earnings per share. Amgen's quarterly revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts forecast that Amgen Inc. will post 22.18 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. Amgen's payout ratio is 70.84%.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.